Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Overview

The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.

Full Title of Study: “Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 15, 2017

Detailed Description

Wiskott Aldrich Syndrome is an X-linked disease characterized by immunodeficiency, eczema and thrombocytopenia; a milder form of the disease known as X-Linked thrombocytopenia also exists. The thrombocytopenia in both WAS and XLT is characterized by: severe thrombocytopenia with platelet counts frequently less than 10-30,000/ul; small platelets which may be dysfunctional; and, as a result, a high rate of serious bleeding including intracranial hemorrhage. Because eltrombopag has been shown to be remarkably efficacious in substantially increasing platelet counts in a high percentage of ITP patients, this study seeks to effectively treat patients who exhibit similar pathologies, as well as evaluate the state of platelets in patients with WAS and relate it to clinical bleeding. It also aims to demonstrate whether eltrombopag administered daily will enhance stem cell function, increase platelet production and platelet count, and reduce bleeding in patients with WAS.

Interventions

  • Drug: Promacta
    • WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests. they will also have diagnostic blood testing prior to initiating treatment
  • Diagnostic Test: blood drawing in patients with WAS
    • blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
  • Diagnostic Test: blood drawing in healthy controls
    • blood will be drawn once in healthy children as controls for platelet parameters

Arms, Groups and Cohorts

  • Experimental: WAS patients receiving Promacta
    • Promacta┬« is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
  • Experimental: WAS patients for blood drawing only
    • WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
  • Placebo Comparator: healthy children for blood drawing only
    • healthy children having blood obtained once as controls for platelet parameters study

Clinical Trial Outcome Measures

Primary Measures

  • How Many WAS Patients Will Achieve Platelet Counts Above 50,000/ul.
    • Time Frame: 12 weeks
    • number of WAS patients achieving this increase to > 50,000/uL without rescue medication in the previous 3 weeks during eltrombopag treatment

Secondary Measures

  • Number of Patients With Wiskott-Aldrich Syndrome (WAS) With Grade 3 or Higher Bleeding or SAE (on WHO Scale)
    • Time Frame: 12 Weeks
    • number of patients with bleeding SAEs while on treatment and/or number of patients with grade 3 or higher bleeding on WHO (World Health Organization) scale: the scale is from 1 to 5 with 5 = fatality and 1=very little bleeding
  • How Many Patients With WAS Had Abnormal Platelet Function Including Activation
    • Time Frame: 12 weeks
    • in how many patients with WAS were platelets dysfunctional or activated before treatment as measured by flow cytometry to a substantial degree and the same after treatment with eltrombopag
  • How Many Patients With WAS Had Substantially Increased Platelet Production After Eltrombopag
    • Time Frame: 12 weeks
    • in how many patients with WAS did eltrombopag increase platelet production as measured by the immature platelet fraction (IPF), a variable derived from the Sysmex auto analyzer, which is considered to be a measure of newly formed platelets ie reticulated platelets

Participating in This Clinical Trial

Inclusion Criteria

In order to be eligible for study entry, subjects must comply with the following:

  • Males from 3 months old to 80 years old – Signed written informed consent obtained prior to study entry – Clinical diagnosis of WAS or XLT – Platelet levels less than 100 x 109/L – Adequate renal and hepatic function (creatinine and bilirubin less than or equal to 1.5 x IULN, AST and ALT less than or equal to 2.5 x IULN) Exclusion Criteria:

Any patient is ineligible for study entry if he/she:

  • Over the age of 80 – Women (only males are eligible) – fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study or until at least 6 months after treatment – Aspirin, aspirin-containing compounds, salicylates, non-steroidal anti-inflammatory medications (NSAIDS), clopidogrel or ticlopidine, warfarin or other vitamin K antagonists, unfractionated or low molecular heparin within 7 days of first infusion – Red blood cell transfusion in the past four weeks – Elevated (> 1.5 x ULN) prothrombin time (PT) or partial thromboplastin time (PTT) – New York Heart Classification III or IV heart disease. Other severe cardiovascular or cardiopulmonary disease, including COPD. – Known HIV infection, hepatitis B or C infection – Any infection requiring antibiotic treatment within 3 days – Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. – Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma skin cancers and carcinoma in situ of the cervix

Gender Eligibility: Male

Minimum Age: 3 Months

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Weill Medical College of Cornell University
  • Collaborator
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • James B Bussel, MD, Principal Investigator, Weill Medical College of Cornell University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.